| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.75B | 84.04B | 64.20B | 57.74B | 44.46B | 26.60B |
| Gross Profit | 22.55B | 25.38B | 19.11B | 13.88B | 12.80B | 10.28B |
| EBITDA | 11.01B | 12.46B | 9.56B | 6.94B | 6.10B | 4.91B |
| Net Income | 3.49B | 4.35B | 4.91B | 4.42B | 4.26B | 3.14B |
Balance Sheet | ||||||
| Total Assets | 116.86B | 117.22B | 112.95B | 54.33B | 47.85B | 37.26B |
| Cash, Cash Equivalents and Short-Term Investments | 2.99B | 3.83B | 4.16B | 913.20M | 4.84B | 2.59B |
| Total Debt | 52.52B | 55.71B | 49.83B | 10.29B | 7.86B | 7.24B |
| Total Liabilities | 78.02B | 80.13B | 80.45B | 25.94B | 21.62B | 17.83B |
| Stockholders Equity | 38.71B | 36.97B | 32.47B | 28.30B | 26.14B | 19.35B |
Cash Flow | ||||||
| Free Cash Flow | 4.09B | -133.30M | 5.70B | -3.92B | -157.80M | 2.70B |
| Operating Cash Flow | 8.22B | 7.60B | 11.05B | 5.04B | 2.90B | 3.85B |
| Investing Cash Flow | -4.06B | -6.90B | -42.14B | -5.52B | -5.41B | -2.03B |
| Financing Cash Flow | -5.18B | -639.30M | 33.81B | -305.70M | 2.17B | -1.80B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹96.61B | 1,460.95 | ― | 1.94% | 6.12% | -30.31% | |
68 Neutral | ₹61.88B | 11.49 | ― | 2.80% | 15.25% | 26.49% | |
67 Neutral | ₹117.37B | 23.48 | ― | 0.62% | 64.80% | 151.92% | |
63 Neutral | ₹149.37B | 25.48 | ― | 0.26% | 8.26% | -34.62% | |
63 Neutral | ₹47.13B | 700.00 | ― | 0.92% | 0.91% | 18.12% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹65.70B | 48.28 | ― | 0.62% | 3.95% | 8.28% |
PCBL Chemical Limited’s Fund Raising Committee has approved amendments to its existing debenture trust deed dated January 20, 2024, specifically to defer testing of a key financial covenant linked to the ratio of consolidated gross debt to EBITDA for the 2025-2026 period. The move suggests the company is seeking greater financial flexibility in meeting covenant requirements, which may ease near-term pressure on its balance sheet and support operational or strategic initiatives funded by its non-convertible debentures.
Following the board committee’s approval, PCBL Chemical has requested that debenture trustee Catalyst Trusteeship Limited convene a meeting of holders of its ₹700 crore non-convertible debentures, identified by ISIN INE602A07020, on March 13, 2026, at shorter notice to ratify the covenant deferral. Securing debenture holder consent will be crucial for implementing the amended terms, with potential implications for investor protections and the company’s financing flexibility in the coming financial years.
PCBL Chemical Limited has announced that its wholly owned subsidiary, PCBL (TN) Limited, has commenced commercial production on Line-4 at its plant from 28 January 2026, adding 60,000 metric tonnes per annum of carbon black capacity as part of a brownfield expansion. This capacity addition, on top of an existing 147,000 MTPA with 87% utilization, is aimed at meeting rising market requirements and should strengthen the company’s ability to serve growing demand, enhance operational scale, and potentially improve its competitive position in the carbon black market.